Suuronen T, Kolehmainen P, Salminen A
Department of Neuroscience and Neurology, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finland.
Biochem Pharmacol. 2000 Jun 15;59(12):1589-95. doi: 10.1016/s0006-2952(00)00282-3.
L-Deprenyl, an irreversible MAO-B (monoamine oxidase B, EC 1.4.3.4) inhibitor, is used for the treatment of Parkinson's disease and to delay the progression of Alzheimer's disease. L-Deprenyl also exhibits protective effects against neuronal apoptosis which are independent of its ability to inhibit MAO-B. The purpose of this study was to compare the antiapoptotic efficacy of L-deprenyl against different types of apoptotic inducers in three neuronal cell culture models. The level of apoptosis was quantified by measuring the activation of caspase-3 enzyme, which is the main apoptotic executioner in neuronal cells. MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] and LDH (lactate dehydrogenase, EC 1. 1.1.27) assays were used to demonstrate the cytotoxic response of apoptotic treatments. Our results showed that okadaic acid, an inhibitor of protein phosphatase 1 and 2A, induced a prominent increase in caspase-3 activity both in cultured hippocampal and cerebellar granule neurons as well as in Neuro-2a neuroblastoma cells. Interestingly, L-deprenyl offered a significant protection against the apoptotic response induced by okadaic acid in all three neuronal models. The best protection appeared at the concentration level of 10(-9) M. L-Deprenyl also provided a protection against apoptosis after AraC (cytosine beta-D-arabinoside) treatment in hippocampal neurons and Neuro-2a cells and after etoposide treatment in Neuro-2a cells. However, L-deprenyl did not offer any protection against apoptosis caused by serum withdrawal or potassium deprivation. Okadaic acid treatment in vivo is known to induce an Alzheimer's type of hyperphosphorylation of tau protein, formation of beta-amyloid plaques, and a severe memory impairment. Our results show that the okadaic acid model provides a promising tool to study the molecular basis of Alzheimer's disease and to screen the neuroprotective capacity of L-deprenyl derivatives.
L-司来吉兰是一种不可逆的单胺氧化酶B(MAO-B,EC 1.4.3.4)抑制剂,用于治疗帕金森病和延缓阿尔茨海默病的进展。L-司来吉兰还具有独立于其抑制MAO-B能力之外的对神经元凋亡的保护作用。本研究的目的是在三种神经元细胞培养模型中比较L-司来吉兰对不同类型凋亡诱导剂的抗凋亡效果。通过测量半胱天冬酶-3(神经元细胞中主要的凋亡执行者)的激活来定量凋亡水平。采用MTT[3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐]和LDH(乳酸脱氢酶,EC 1.1.1.27)检测来证明凋亡处理的细胞毒性反应。我们的结果表明,冈田酸(一种蛋白磷酸酶1和2A的抑制剂)在培养的海马和小脑颗粒神经元以及Neuro-2a神经母细胞瘤细胞中均诱导半胱天冬酶-3活性显著增加。有趣的是,在所有三种神经元模型中,L-司来吉兰对冈田酸诱导的凋亡反应均提供了显著的保护作用。最佳保护作用出现在10(-9)M的浓度水平。L-司来吉兰在海马神经元和Neuro-2a细胞经阿糖胞苷(β-D-阿拉伯糖胞嘧啶)处理后以及Neuro-2a细胞经依托泊苷处理后也提供了抗凋亡保护作用。然而,L-司来吉兰对血清剥夺或钾缺乏引起的凋亡没有提供任何保护作用。已知在体内用冈田酸处理会诱导tau蛋白的阿尔茨海默病样过度磷酸化、β-淀粉样斑块的形成以及严重的记忆障碍。我们的结果表明,冈田酸模型为研究阿尔茨海默病的分子基础和筛选L-司来吉兰衍生物的神经保护能力提供了一个有前景的工具。